CoChat

Desmopressin duration of antidiuretic action in patients with central diabetes insipidus

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The key question answered by this study is whether it is possible to deliver a pharmacokinetic and pharmacodynamic duration of antidiuretic action long enough to ensure adequate antidiuresis with two daily administrations of desmopressin in patients with central diabetes insipidus (CDI). We studied the efficacy and safety of desmopressin i.v. in 13 CDI patients using two 3-way crossover designs, in the doses 30, 60, 125 ng, and 125, 250 and 500 ng. Duration of action, minimum output rate, max osmolality and average osmolality during action (AUC osmolality) were measured every 30 min for the first 2 h during the infusion, and then every hour or every second hour until the urine output rate was greater than 2 ml/kg/30 min. The duration of antidiuretic action was 4, 8 and 11 h, respectively, for 125, 250, and 500 ng, increasing from 250 to 500 ng but for the remaining secondary dynamic efficacy parameters no difference could be detected based on descriptive statistics between the doses 250 and 500 ng, indicating that the upper plateau region of the dose-response curve had been reached. All treatment emergent adverse events were classified as unrelated or unlikely related to trial medication. No serious adverse events occurred. Data on duration of action indicates that it is possible to achieve antidiuretic control with 500 ng i.v. corresponding to 160 μg orodispersible tablets twice daily in CDI patients. Today, the Minirin Melt label recommends the majority of CDI patients a do…

Overview

Integrity signals

Registry

Crossref · 10.1007/s12020-011-9492-z

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 11 references

Research works printed but not linked: 2

  1. H. Vilhardt, Expert Report Oral dDAVP in Diabetes Insipidus and Nocturnal Enuresis (University of Copenhagen, Denmark, 1993)
  2. R.W. Schrier, in Section XI: Disorders of electrolyte, water, and acid-base. Diseases of the Kidney and Urinary Tract (Lippincott Williams & Wilkins, 2007), p. 2223

Cited by

See all 27

Metadata

Authors
Juul, K. V., Bichet, D. G., & Nørgaard, J. P.
Affiliations
  • Ferring Pharmaceuticals (Denmark) (DK)
  • Hôpital du Sacré-Cœur de Montréal (CA)
  • Lund University (SE)
Corresponding author
Juul, Kristian Vinter
Venue
Endocrine
Published
2011-05-29
Volume
40
Issue
1
Pages
67-74
ISSN
  • 0969-711X (ISSN-L)
  • 1355-008X
  • 1559-0100
OpenAlex
W2160190817
Cited by
26
References
11
Citations by year
2026: 2 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 3 · 2019: 3 · 2018: 1 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 3
FWCI
2.18
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Endocrine (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Electrolyte and hormonal disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
desmopressin, central diabetes insipidus, intravenous administration, dose-response relationship, osmolality, urine output, orally disintegrating tablets, treatment-emergent adverse events
MeSH terms
Administration, Oral, Adult, Deamino Arginine Vasopressin, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Osmolar Concentration, Sodium, Thirst, Time Factors, Urine, Treatment Outcome, Cross-Over Studies, Diabetes Insipidus, Neurogenic, Antidiuretic Agents, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. https://app.cochat.ai/papers/10.1007/s12020-011-9492-z
The paper
Juul, K. V., Bichet, D. G., & Nørgaard, J. P. (2011). Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. Endocrine. https://doi.org/10.1007/s12020-011-9492-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.